DSL’s GI-MAP stool test is, as CEO Tony Hoffman states, “a clinician diagnostic tool;” it’s not a microbiome test. Yes, of course the GI-MAP looks at the microbiome, but it's not a broad sweep of the myriad of bugs taking up residence. Rather, it’s a carefully curated investigation of organisms with demonstrated imbalance potential, be it pathogenic or dysbiotic in nature. The test is designed to be user-friendly, interpreted rapidly, logically, providing clearly actionable data that, when addressed, gets results. I’ve known Tony for years; we were both involved in the development of the first stool test using PCR analysis offered to clinicians. He’s brilliant, fun to listen to, and offers loads of pearls in this conversation. Take a listen, share, comment, and let us know what you think!
Dr. Kara Fitzgerald | New Frontiers in Functional Medicine, Longevity, Epigenetics